Results 41 to 50 of about 1,279,543 (154)

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease (Review) [PDF]

, 2011
BackgroundLong-acting bronchodilators comprising long-acting beta(2)-agonists and the anticholinergic agent tiotropiumare commonly used, either on their own or in combination, for managing persistent symptoms of chronic obstructive pulmonary disease ...
Christopher J Cates, Karner, C, Cates, CJ, Charlotta Karner   +3 more
core   +1 more source

Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism [PDF]

, 2020
The manuscript of a paper entitled "Interaction of Synthetic Cannabinoid Receptor Agonists with Cannabinoid Receptor I: Insights into Activation Molecular Mechanism".
Anton, Bashilov, Sergei, Gavryushov, Nikolay, Kuzmich, Boris, Izotov, Konstantin, Cherashev-Tumanov, Tatyana, Burykina   +5 more
core   +2 more sources

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

Journal of Pharmacy & Pharmaceutical Sciences
Excess adiposity can contribute to metabolic complications, such as type 2 diabetes mellitus (T2DM), which poses a significant global health burden.
Arianne Morissette, Erin E. Mulvihill, Erin E. Mulvihill   +2 more
doaj   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Biotinyl analogues of amylin as biologically active probes for amylin/CGRP receptor recognition [PDF]

, 1992
Biotinyl analogues of rat amylin were synthesised with sulfosuccinimidyl 2-(biotinamido)ethyl-1,3-dithiopropionate(NHS-SS-Biotin). Biotinylated amylin peptides were purified by HPLC, quantitated, and the presence of the biotin group at Lys-1 confirmed by
Foot, Elizabeth A., Day, Anthony J., Willis, Antony C., Leighton, Brendan, Day, Anthony J.; id_orcid, Brendan Leighton, Antony C. Willis, Elizabeth A. Foot, Chantry, Andrew, Andrew Chantry, Anthony J. Day   +10 more
core   +1 more source

Does Incretin Agonism Have Sustainable Efficacy?

Cells
Recent clinical trials using synthetic incretin hormones, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists have demonstrated that these treatments ameliorated many complications related to obesity,
Sok-Ja Janket, Miyo K. Chatanaka, Dorsa Sohaei, Faleh Tamimi, Jukka H. Meurman, Eleftherios P. Diamandis   +5 more
doaj   +1 more source

Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek, Hajnalka Lőrincz, Mariann Harangi, Attila Csaba Nagy   +3 more
wiley   +1 more source

GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies

Pharmacological Research
The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) represents a major breakthrough in the pharmacotherapy of obesity. However, their single-target mechanism has limitations.
Xinyao Wang, Rutao Lin, Qinmei Sun, Xin Xin, Qin Feng   +4 more
doaj   +1 more source

Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids.

PLoS ONE, 2013
Combination therapy is being increasingly used as a treatment paradigm for metabolic diseases such as diabetes and obesity. In the peptide therapeutics realm, recent work has highlighted the therapeutic potential of chimeric peptides that act on two ...
James L Trevaskis, Christine M Mack, Chengzao Sun, Christopher J Soares, Lawrence J D'Souza, Odile E Levy, Diane Y Lewis, Carolyn M Jodka, Krystyna Tatarkiewicz, Bronislava Gedulin, Swati Gupta, Carrie Wittmer, Michael Hanley, Bruce Forood, David G Parkes, Soumitra S Ghosh   +15 more
doaj   +1 more source